Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Wight, J; Hamad, N; Campbell, BA; Ku, M; Lee, K; Rose, H; Armytage, T; Latimer, M; Lee, HP; Lee, ST; Dickinson, M; Khor, R; Verner, E

Author(s): Wight, J; Hamad, N; Campbell, BA; Ku, M; Lee, K; Rose, H; Armytage, T; Latimer, M; Lee, HP; Lee, ST; Dickinson, M; Khor, R; Verner, E;
Details: Publication Year 2022-09,Volume 52,Issue #9,Page 1609-1623
Journal Title: Internal Medicine Journal
Publication Type: Guideline
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.
Keywords: Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Consensus; *Hematopoietic Stem Cell Transplantation; Humans; *Lymphoma, Large B-Cell, Diffuse/diagnosis/therapy; Rituximab/therapeutic use; Transplantation, Autologous; diagnosis; diffuse large B-cell lymphoma; management; prognosis
Department(s): Haematology
PubMed ID: 34532916
Publisher's Version: https://doi.org/10.1111/imj.15533
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-09 07:31:44

Last Modified: 2025-05-09 07:33:16